Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07203677 · ClinicalTrials.gov registry record
Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)
A clinical trial of Atherosclerotic Cardiovascular Disease and Type2 Diabetes Mellitus, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 49,065
- Enrollment target
- 1
- Study location
NCT07203677 is a study of Atherosclerotic Cardiovascular Disease and Type2 Diabetes Mellitus that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 49,065 participants, above the 5,231-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (838% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07203677, a study of Atherosclerotic Cardiovascular Disease and Type2 Diabetes Mellitus, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 49,065 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions Studied
Interventions
- DRUG Initiation of tirzepatide
- DRUG Initiation of sitagliptin
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49,065 participants |
| Start Date | 2025-09-19 |
| Est. Completion | 2025-10-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07203677
The ClinicalTrials.gov registry entry for NCT07203677 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 49,065 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 5,231-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (838% higher). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atherosclerotic Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Initiation of tirzepatide is the first listed.
NCT07203677 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07203677 about?
NCT07203677 is a clinical study titled "Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)". Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such s...
What is the current status of trial NCT07203677?
This trial is currently completed. The enrollment target is 49,065 participants. The study started on 2025-09-19. Estimated completion is 2025-10-15.
What conditions does trial NCT07203677 study?
This clinical trial studies the following conditions: Atherosclerotic Cardiovascular Disease, Type2 Diabetes Mellitus.
What interventions are being tested in trial NCT07203677?
The interventions under investigation include: Initiation of tirzepatide (DRUG), Initiation of sitagliptin (DRUG).
Who is sponsoring clinical trial NCT07203677?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07203677 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerotic Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients
RECRUITING · NA
-
The Prevent Coronary Artery Disease Trial
RECRUITING · Phase 3
-
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
RECRUITING · Phase 3
-
Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure
RECRUITING · NA
-
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
RECRUITING · Phase 2
-
Pelacarsen Roll-over Extension Program
RECRUITING · Phase 3
Explore more on PlainTrial
Atherosclerotic Cardiovascular Disease
All registered trials for this condition
Type2 Diabetes Mellitus
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.